Scientific Reports,
Год журнала:
2024,
Номер
14(1)
Опубликована: Авг. 13, 2024
To
address
the
challenge
of
finding
new
combination
therapies
against
castration-sensitive
prostate
cancer,
we
introduce
Vini,
a
computational
tool
that
predicts
efficacy
drug
combinations
at
intracellular
level
by
integrating
data
from
KEGG,
DrugBank,
Pubchem,
Protein
Data
Bank,
Uniprot,
NCI-60
and
COSMIC
databases.
Vini
is
drugs
their
level.
It
addresses
problem
comprehensively
considering
all
known
target
genes,
proteins
small
molecules
mutual
interactions
involved
in
onset
development
cancer.
The
results
obtained
point
to
new,
previously
unexplored
could
theoretically
be
promising
candidates
for
treatment
cancer
prevent
inevitable
progression
incurable
castration-resistant
stage.
Furthermore,
after
analyzing
triple
targets,
most
common
targets
became
clear:
ALK,
BCL-2,
mTOR,
DNA
androgen
axis.
These
may
help
define
future
use
computer
model
explore
therapeutic
represents
an
innovative
approach
search
effective
treatments
which,
if
clinically
validated,
potentially
lead
breakthrough
therapies.
Expert Opinion on Drug Discovery,
Год журнала:
2024,
Номер
19(7), С. 841 - 853
Опубликована: Июнь 11, 2024
Introduction
Prostate
cancer
(PC)
is
the
most
common
malignancy
and
accounts
for
a
significant
proportion
of
deaths
among
men.
Although
initial
therapy
success
can
often
be
observed
in
patients
diagnosed
with
localized
PC,
many
eventually
develop
disease
recurrence
metastasis.
Without
effective
treatments,
aggressive
PC
display
very
poor
survival.
To
curb
current
high
mortality
rate,
investigations
have
been
carried
out
to
identify
efficacious
therapeutics.
Compared
de
novo
drug
designs,
computational
methods
widely
employed
offer
actionable
predictions
fast
cost-efficient
way.
Particularly,
powered
by
an
increasing
availability
next-generation
sequencing
molecular
profiles
from
patients,
computer-aided
approaches
tailored
screen
candidate
drugs.
JCO Precision Oncology,
Год журнала:
2023,
Номер
7
Опубликована: Сен. 1, 2023
Given
the
high
attrition
rate
of
de
novo
drug
discovery
and
limited
efficacy
single-agent
therapies
in
cancer
treatment,
combination
therapy
prediction
through
silico
repurposing
has
risen
as
a
time-
cost-effective
alternative
for
identifying
novel
potentially
efficacious
cancer.
The
purpose
this
review
is
to
provide
an
introduction
computational
methods
summarize
recent
studies
that
implement
each
these
methods.
A
systematic
search
PubMed
database
was
performed,
focusing
on
published
within
past
10
years.
Our
included
reviews
articles
ongoing
retrospective
studies.
We
prioritized
with
findings
suggest
considerations
improving
over
providing
meta-analysis
all
currently
available
Computational
used
research
include
networks,
regression-based
machine
learning,
classifier
learning
models,
deep
approaches.
Each
method
class
its
own
advantages
disadvantages,
so
careful
consideration
needed
determine
most
suitable
when
designing
method.
Future
directions
improve
current
technology
incorporation
disease
pathobiology,
characteristics,
patient
multiomics
data,
drug-drug
interactions
maximally
tolerable
regimens
As
their
capability
integrate
patient,
drug,
more
comprehensive
models
can
be
developed
accurately
predict
safe
other
complex
diseases.
Scientific Reports,
Год журнала:
2024,
Номер
14(1)
Опубликована: Авг. 13, 2024
To
address
the
challenge
of
finding
new
combination
therapies
against
castration-sensitive
prostate
cancer,
we
introduce
Vini,
a
computational
tool
that
predicts
efficacy
drug
combinations
at
intracellular
level
by
integrating
data
from
KEGG,
DrugBank,
Pubchem,
Protein
Data
Bank,
Uniprot,
NCI-60
and
COSMIC
databases.
Vini
is
drugs
their
level.
It
addresses
problem
comprehensively
considering
all
known
target
genes,
proteins
small
molecules
mutual
interactions
involved
in
onset
development
cancer.
The
results
obtained
point
to
new,
previously
unexplored
could
theoretically
be
promising
candidates
for
treatment
cancer
prevent
inevitable
progression
incurable
castration-resistant
stage.
Furthermore,
after
analyzing
triple
targets,
most
common
targets
became
clear:
ALK,
BCL-2,
mTOR,
DNA
androgen
axis.
These
may
help
define
future
use
computer
model
explore
therapeutic
represents
an
innovative
approach
search
effective
treatments
which,
if
clinically
validated,
potentially
lead
breakthrough
therapies.